Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PRV-300 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| PRV-300 | BIOLOGICAL | Treatment |
| Placebo | BIOLOGICAL | Control |
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Sanofi SA Sponsored ADR | SNY | 8 | PHASE3 | Duvakitug |
| Eli Lilly and Company | LLY | 8 | PHASE3 | Mirikizumab |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 10 | PHASE3 | Vedolizumab |
| Johnson & Johnson | JNJ | 13 | PHASE3 | Ustekinumab |
| AbbVie, Inc. | ABBV | 14 | PHASE3 | Upadacitinib |
| Merck & Co., Inc. | MRK | 3 | PHASE3 | Tulisokibart |
| Pfizer Inc. | PFE | 8 | PHASE3 | Etrasimod |
| Gilead Sciences, Inc. | GILD | 3 | PHASE3 | Filgotinib |
| Abivax SA Sponsored ADR | ABVX | 2 | PHASE3 | ABX464 |
| Bristol-Myers Squibb Company | BMY | 5 | PHASE2 | Ozanimod |
| Spyre Therapeutics, Inc | SYRE | 1 | PHASE2 | SPY001, SPY002, SPY003 |
| AnaptysBio, Inc. | ANAB | 1 | PHASE2 | Rosnilimab |
| Palatin Technologies, Inc. | PTN | 1 | PHASE2 | PL8177 |
| GSK plc Sponsored ADR | GSK | 1 | PHASE1 | GSK4528287 |
| Xencor, Inc. | XNCR | 1 | PHASE1 | XmAb942 |
| Sunshine Biopharma Incorporated | SBFM | 1 | PHASE2 | 627 |
| Amgen Inc. | AMGN | 1 | N/A | Undisclosed |
| TScan Therapeutics, Inc. | TCRX | 1 | - | Undisclosed |
PRV-300 is an investigational monoclonal antibody being developed for the treatment of ulcerative colitis. It is intended for adult patients with moderately to severely active ulcerative colitis. The drug is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
PRV-300 is being developed by Sanofi, a multinational pharmaceutical company listed on the stock exchange under the ticker SNY. Sanofi is conducting clinical trials to evaluate the safety of PRV-300 in patients with ulcerative colitis.
PRV-300 is in Phase 1 clinical development. A Phase 1 trial has been completed to evaluate its safety in adult subjects with moderately to severely active ulcerative colitis. The drug is investigational and has not received regulatory approval.
PRV-300 has been studied in one clinical trial with the identifier NCT03849599. This Phase 1 study, titled 'A Study to Evaluate the Safety of PRV-300 in Adult Subjects With Moderately to Severely Active Ulcerative Colitis,' has been completed and enrolled 37 participants.
PRV-300 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development for ulcerative colitis. A Phase 1 trial has been completed, but the drug has not yet received marketing authorization from regulatory agencies.